Overview Dividends

(PHG) Koninklijke Philips - Ratings and Ratios

Exchange: NYSE • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: US5004723038

Imaging Systems, Patient Monitoring, Respiratory Care, Oral Care, Baby Care

Health Care Equipment
Market Cap in USD: 25,515m

IPO / Inception: 1987-12-30
Return 12m vs S&P 500: -5.95%

EPS (Earnings per Share)

EPS CAGR: -14.58%
EPS Trend: 24.1%

Last SUE: -0.11
Qual. Beats: 0

Revenue

Rev. CAGR: -3.64%
Rev. Trend: -6.2%

Last SUE: 0.00
Qual. Beats: 0

Dividends

Dividend Yield	3.60%
Yield on Cost 5y	2.02%
Yield CAGR 5y	-0.57%
Payout Consistency	75.5%
Payout Ratio	67.3%

Risk via 5d forecast
Volatility	32.0%
Value at Risk 5%th	43.9%
Relative Tail Risk	-16.52%

Reward TTM
Sharpe Ratio	0.37
Alpha	-5.56
CAGR/Max DD	0.76

Character TTM
Hurst Exponent	0.318
Beta	0.874
Beta Downside	0.885

Drawdowns 3y
Max DD	33.81%
Mean DD	11.48%
Median DD	11.00%

Description: PHG Koninklijke Philips December 17, 2025

Koninklijke Philips N.V. (NYSE: PHG) is a Dutch-based health-technology firm that serves North America, Greater China, and other international markets through three operating segments: Diagnosis & Treatment, Connected Care, and Personal Health.

In Diagnosis & Treatment, Philips supplies a full suite of imaging equipment-including MRI, X-ray, CT (with detector-based spectral CT), and ultrasound systems-as well as interventional X-ray platforms and software that support minimally invasive cardiac, vascular, and electrophysiology procedures.

The Connected Care segment focuses on acute patient-management tools, emergency-care solutions, home-care platforms, and vendor-agnostic software that enable remote monitoring and workflow integration across hospitals and ambulatory settings.

Personal Health delivers consumer-oriented products such as power toothbrushes, infant-feeding devices, digital parental and women’s health solutions, and grooming/beauty items, leveraging Philips’ brand equity in the household market.

Key recent metrics (FY 2023): revenue of $21.2 billion, up ~6 % YoY; operating margin of ~10 %; and R&D spending of roughly 5 % of sales, reflecting continued investment in AI-driven imaging and digital health platforms. The global medical imaging market is projected to grow at a 5 % CAGR through 2029, driven by an aging population and rising demand for early disease detection.

Assumption: the FY 2023 figures are based on Philips’ published annual report; any forward-looking statements about market growth rely on consensus estimates from industry research firms (e.g., Grand View Research). If actual R&D intensity or margin trends diverge, the growth outlook could shift materially.

For a deeper, data-rich assessment of Philips’ valuation dynamics, you may find the analyst tools on ValueRay worth a quick look.

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (165.0m TTM) > 0 and > 6% of Revenue (6% = 1.07b TTM)

FCFTA 0.01 (>2.0%) and ΔFCFTA -7.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 12.64% (prev -35.92%; Δ 48.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 1.11b > Net Income 165.0m (YES >=105%, WARN >=100%)

Net Debt (6.47b) to EBITDA (2.33b) ratio: 2.78 <= 3.0 (WARN <= 3.5)

Current Ratio 1.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (963.8m) change vs 12m ago 5.56% (target <= -2.0% for YES)

Gross Margin 43.49% (prev 42.18%; Δ 1.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 92.95% (prev 151.3%; Δ -58.39pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 4.11 (EBITDA TTM 2.33b / Interest Expense TTM 276.0m) >= 6 (WARN >= 3)

Altman Z'' 2.27

(A) 0.09 = (Total Current Assets 9.28b - Total Current Liabilities 7.03b) / Total Assets 26.34b

(B) 0.12 = Retained Earnings (Balance) 3.21b / Total Assets 26.34b

(D) 0.87 = Book Value of Equity 13.76b / Total Liabilities 15.76b

Total Rating: 2.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 48.27

1. Piotroski 4.0pt

2. FCF Yield 1.13%

3. FCF Margin 1.79%

4. Debt/Equity 0.79

5. Debt/Ebitda 2.78

6. ROIC - WACC (= -2.68)%

7. RoE 1.48%

8. Rev. Trend -6.22%

9. EPS Trend 24.14%

What is the price of PHG shares?

As of December 24, 2025, the stock is trading at USD 26.88 with a total of 307,893 shares traded.
Over the past week, the price has changed by +1.32%, over one month by -1.79%, over three months by -3.31% and over the past year by +10.08%.

Is PHG a buy, sell or hold?

Koninklijke Philips has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy PHG.

Strong Buy: 1
Buy: 1
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the PHG price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	33.4	24.3%
Analysts Target Price	33.4	24.3%
ValueRay Target Price	26.7	-0.8%

PHG Fundamental Data Overview December 24, 2025

Market Cap EUR = 21.76b (25.51b USD * 0.853 USD.EUR)
P/E Trailing = 141.2105
P/E Forward = 14.9254
P/S = 1.435
P/B = 2.0656
P/EG = 0.3632
Beta = 0.907
Revenue TTM = 17.78b EUR
EBIT TTM = 1.13b EUR
EBITDA TTM = 2.33b EUR
Long Term Debt = 7.24b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.15b EUR (from shortTermDebt, last quarter)
Debt = 8.38b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.47b EUR (from netDebt column, last quarter)
Enterprise Value = 28.24b EUR (21.76b + Debt 8.38b - CCE 1.91b)
Interest Coverage Ratio = 4.11 (Ebit TTM 1.13b / Interest Expense TTM 276.0m)
FCF Yield = 1.13% (FCF TTM 318.2m / Enterprise Value 28.24b)
FCF Margin = 1.79% (FCF TTM 318.2m / Revenue TTM 17.78b)
Net Margin = 0.93% (Net Income TTM 165.0m / Revenue TTM 17.78b)
Gross Margin = 43.49% ((Revenue TTM 17.78b - Cost of Revenue TTM 10.05b) / Revenue TTM)
Gross Margin QoQ = 44.40% (prev 46.36%)
Tobins Q-Ratio = 1.07 (Enterprise Value 28.24b / Total Assets 26.34b)
Interest Expense / Debt = 0.68% (Interest Expense 57.0m / Debt 8.38b)
Taxrate = 31.64% (87.0m / 275.0m)
NOPAT = 774.6m (EBIT 1.13b * (1 - 31.64%))
Current Ratio = 1.32 (Total Current Assets 9.28b / Total Current Liabilities 7.03b)
Debt / Equity = 0.79 (Debt 8.38b / totalStockholderEquity, last quarter 10.55b)
Debt / EBITDA = 2.78 (Net Debt 6.47b / EBITDA 2.33b)
Debt / FCF = 20.34 (Net Debt 6.47b / FCF TTM 318.2m)
Total Stockholder Equity = 11.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.63% (Net Income 165.0m / Total Assets 26.34b)
RoE = 1.48% (Net Income TTM 165.0m / Total Stockholder Equity 11.16b)
RoCE = 6.16% (EBIT 1.13b / Capital Employed (Equity 11.16b + L.T.Debt 7.24b))
RoIC = 4.11% (NOPAT 774.6m / Invested Capital 18.86b)
WACC = 6.79% (E(21.76b)/V(30.15b) * Re(9.23%) + D(8.38b)/V(30.15b) * Rd(0.68%) * (1-Tc(0.32)))
Discount Rate = 9.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.52%
[DCF Debug] Terminal Value 65.28% ; FCFE base≈599.7m ; Y1≈393.7m ; Y5≈180.1m
Fair Price DCF = 3.08 (DCF Value 2.93b / Shares Outstanding 951.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 24.14 | EPS CAGR: -14.58% | SUE: -0.11 | # QB: 0
Revenue Correlation: -6.22 | Revenue CAGR: -3.64% | SUE: -0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=1.78 | Chg30d=-0.038 | Revisions Net=+1 | Growth EPS=+10.8% | Growth Revenue=+1.6%

Additional Sources for PHG Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle